Nervgen Pharma (NGEN) Shares Outstanding (2024 - 2026)
Nervgen Pharma (NGEN) posted quarterly Shares Outstanding (Entity) of $79.9 million for Q1 2026, up 13.07% year-over-year from $70.7 million in Q1 2025, and up 10.47% quarter-over-quarter from $72.3 million in Q4 2025.
Nervgen Pharma (NGEN) Shares Outstanding (2024 - 2026) Analysis & Trends
Nervgen Pharma (NGEN) has reported Shares Outstanding (Entity) for 3 consecutive years, with $79.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 13.07% year-over-year to $79.9 million; the TTM figure through Mar 2026 stood at $79.9 million (up 13.07% YoY), while the FY2025 annual figure was $72.3 million, up 7.44% from the prior year.
- Shares Outstanding (Entity) advanced to $79.9 million in Q1 2026 per NGEN's latest filing, from $72.3 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $79.9 million in Q1 2026 and bottomed at $67.3 million in Q4 2024.
- Historically, Shares Outstanding (Entity) has averaged $72.6 million across 3 years, with a median of $71.5 million in 2025.
- Annual changes were most pronounced in 2025 — Shares Outstanding (Entity) rose 7.44% — and 2026, when it advanced 13.07%.
- Nervgen Pharma's Shares Outstanding (Entity) stood at $67.3 million in 2024, then gained by 7.44% to $72.3 million in 2025, then gained by 10.47% to $79.9 million in 2026.
- Business Quant data shows NGEN's Shares Outstanding (Entity) at $79.9 million in Q1 2026, $72.3 million in Q4 2025, and $70.7 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Nervgen Pharma | 168.94 Mn | 168.94 Mn | - | 92.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 79.90 Mn |
| Dec 31, 2025 | 72.33 Mn |
| Mar 31, 2025 | 70.67 Mn |
| Dec 31, 2024 | 67.32 Mn |